NCT03834441 is a NA clinical trial of Oral HRSN screening in Emergencies, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT03834441?

NCT03834441 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT03834441?

Interventions in NCT03834441: Oral HRSN screening, Written HRSN screening.

What condition does NCT03834441 study?

NCT03834441 studies Emergencies.

Is NCT03834441 still recruiting?

NCT03834441 is currently completed. Last updated 9 February 2023.

Are results published for NCT03834441?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-02-09 · How we verify

NCT03834441

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimized Health-Related Social Needs Screening and Community Linkages

Completed NA Results posted Last updated 9 February 2023

What this trial tests

NA trial testing Oral HRSN screening in Emergencies in 236 participants. Completed in 20 February 2020.

Timeline

7 May 2019

Primary endpoint
1 September 2019

20 February 2020

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	236
Start date	7 May 2019
Primary completion	1 September 2019
Estimated completion	20 February 2020
Sites	1 location across United States

Drugs / interventions tested

Oral HRSN screening
Written HRSN screening

Conditions studied

Emergencies — all drugs for Emergencies →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Emergencies. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Self-reported Satisfaction With the Screening Process Primary · Immediately after completing survey

Satisfaction with screening as measured by: Please tell us how satisfied you were with the questionnaire you just took: Extremely Quite a bit Somewhat A little bit Not at all

Group	Value	95% CI
Oral Screening	94
Written Screening	97
Oral Screening	12
Written Screening	15
Oral Screening	9
Written Screening	9

Number of Health Related Social Needs Reported Secondary · Immediately after completing survey

We will record the number of health related social needs reported

Group	Value	95% CI
Oral Screening	70
Written Screening	93
Oral Screening	45
Written Screening	28

Sponsor's own description

The objective of this study is to to understand the most effective method for health-related social need (HRSN) screening in the challenging environment of an emergency department by randomizing patients to oral or written HRSN screening in the ED.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A pilot mixed-methods randomized controlled trial of verbal versus electronic screening for adverse social determinants of health.
Macias-Konstantopoulos W, Ciccolo G, Muzikansky A, Samuels-Kalow M. · · 2022 · cited 13× · PMID 35224551 · DOI 10.1002/emp2.12678

Verify or expand the search:

Other recruiting trials for Emergencies

Currently open trials in the same condition.

NCT06565390 — Remote Oximeter Monitoring Post-discharge to Reduce Emergency Room Visits and Rehospitalization · NA · recruiting
NCT07051668 — The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls · NA · recruiting
NCT06680778 — Pro-active Monitoring of Vital Signs in Oncology Patients Using a Smartwatch · recruiting
NCT07008391 — High-Sensitivity Troponin I in Addition to Guideline-Based Care in EMS · NA · recruiting
NCT07027813 — Feasibility and Efficacy of Ambulance-Based m-Health for Pediatric Emergencies (FEAMER) Trial · NA · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03834441 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 9 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03834441.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing